Given PARP-1’s critical role in DNA damage repair, using PARP-1 inhibitors to enhance the efficacy of anti-cancer treatments could increase tumor cell sensitivity to radiotherapy or chemotherapy (Underhill et al., 2011). This evidence concerns the gene PARP1 and neoplasm.